Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOCERV
NCT04580771Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2020
- Primary completion
- Mar 2027
- Modality
- Peptides, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PDS0101 in Cervical Cancer (CC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2020; status: active, not recruiting.
02
Drugs
PDS0101
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04580771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580771.